Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
NCT05083182Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2022
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of ustekinumab, guselkumab in juvenile psoriatic arthritis (JPsA), sponsored by Janssen Pharmaceutical. Started Aug 2022; status: completed.
02
Drugs
ustekinumabguselkumab
03
Conditions
juvenile psoriatic arthritis (JPsA)
Beyond the preview
Go deeper on NCT05083182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05083182.